Paysign Q3 revenue up 23% to $15.26M; pharma affordability revenue surges 219%

Paysign, Inc.

2024-Q3 EPS reported $0.04 revenue$42,778,104

Total revenues $15.26M (+23% YoY); net income $1.44M ($0.03 diluted EPS) vs $1.10M ($0.02) prior year.
Pharma patient affordability revenue surged 219.1% YoY, now 21.5% of total revenue; 66 active programs at quarter end.
Adjusted EBITDA $2.83M (+20.6% YoY); FY2024 guidance reaffirmed: rev $56.5-58.5M, adj. EBITDA $9-10M.
Plasma revenue up 3.4% YoY from 478 centers; average monthly revenue per center $7,991, down slightly from $8,041.
Unrestricted cash $10.29M, zero debt; Q4 legal expense expected for class action settlement but within guidance.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.